- lactic acid
This information is intended for use by health professionals
Calmurid 10%/5% w/w Cream
One gram of cream contains 100 mg of Urea and 50 mg of Lactic acid
For the full list of excipients, see section 6.1
A homogenous, white, oil-in-water cream
To be applied topically for the correction of hyperkeratosis and dryness in ichthyosis and allied conditions characterised by dry, rough, scaly skin.
For external use only.
Adults, elderly and children:
A thick layer of Calmurid is applied twice daily after washing the affected area. The cream is left on the skin for 3-5 minutes and then rubbed lightly in. Excess cream should be wiped off the skin with a tissue, not washed off. Frequency of application can be reduced as the patient progresses. In hyperkeratosis of the feet apply Calmurid as above after soaking the feet in warm water for 15 minutes and drying with a rough towel.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Calmurid should not be used extensively in patients with severe renal impairement.
Calmurid is acidic and hypertonic and can cause smarting if applied to raw areas, fissures or mucous membranes. Where this is a barrier to therapy the use of Calmurid diluted 50% with aqueous cream B.P. for one week should result in freedom from smarting upon use of Calmurid.
Avoid contact with the eyes and surrounding area and do not apply Calmurid on inflamed skin or open wounds.
Low pH of cream might affect stability of other drugs.
Urea may enhance the penetration of other active substances into the skin. This is particularly well-known for corticosteroids, dithranol and 5-fluoruracil.
There is no specific data available regarding the use in pregnant women and during lactation.
In breast-feeding woman Calmurid should be removed from the breast area before breast feeding.
Calmurid has no or negligible influence on the ability to drive and use machines.
Calmurid is acidic and hypertonic and can cause smarting if applied to raw areas, fissures or mucous membranes.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard
Unlikely. In the case of smarting, wash the cream off.
Pharmacotherapeutic group: Carbomide products
ATC code: D02AE
Urea at a concentration of 10% has keratolytic, anti microbial, anti pruritic and hydrating effects on the skin. Lactic acid has keratolytic, hydrating and anti microbial properties also. Treatment of ichthyotic patients shows a parallel between clinical improvement and increase in the otherwise depressed binding capacity of the horny layer.
There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the SmPC
Diethanolamine Cetylphosphate (``Amphisol'')
The low pH due to lactic acid means care in choice of other packages or other drugs admixed.
Do not store above 25°C. Do not refrigerate or freeze.
White low density polyethylene tubes fitted with white polypropylene screw caps
Package sizes: 15, 20, 30, 50, 100 g.
White polypropylene bottle fitted with a white polyethylene closure and a natural polyethylene follower plate.
Package sizes: 400, 500 g.
Not all pack sizes may be marketed.
No special requirements.
Galderma (UK) Limited
69-71 Clarendon Road
09th February 1993
Meridien House, 69-71 Clarendon Road, Watford, Hertfordshire, WD17 1DS, UK
+44 (0)1923 208998
+44 (0)1923 208950